Compare Aegon Ltd. (AEG) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aegon Ltd. vs Danaher Corporation — how do they compare? Aegon Ltd. trades at $8.73 (market cap $12.98B), while Danaher Corporation trades at $190.62 (market cap $137.44B). The key difference: Danaher Corporation is far larger — about 10.6× Aegon Ltd.'s market cap, and Aegon Ltd. pays the higher dividend (5.3%). Which is the better fit depends on your goals.
| AEG | DHR | |
|---|---|---|
Market Cap | $12.98B | $137.44B |
Sector | Financials | Health |
52-Week High | $8.79 | $242.05 |
52-Week Low | $6.79 | $161.91 |
Enterprise Value | $14.11B | $150.22B |
Dividend Yield | 5.3% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $8.75, up 1.04% on the day, with a P/E of 12.86 and P/S of 0.55 indicating potential undervaluation. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company is undergoing strategic simplification, including moving its legal seat to Delaware and focusing on U.S. operations, supported by a dividend of $0.25 payable in July 2026. Technical indicators are bullish on moving averages but neutral on oscillators.
Outlook is cautiously optimistic with a 27.78% analyst buy rating, driven by restructuring benefits and U.S. market focus. Risks include execution challenges in the transition, volatile cash flows, and competitive pressures. The stock presents a value opportunity if the strategic pivot succeeds, but investors should monitor earnings consistency and debt management.
Danaher (DHR) trades at $193.62, down 2.18% today but remains in a bullish technical trend with strong support near $190. The company demonstrates solid fundamentals with a 58.94% gross margin and consistent earnings beats in recent quarters. Recent news highlights strategic collaborations and a pending acquisition of Masimo, approved by shareholders in May 2026, signaling growth initiatives.
The outlook is positive with a consensus price target of $214.73, implying 11% upside. Key risks include revenue stagnation and a high P/E ratio of 37.52. Analyst sentiment is strongly bullish (69% buy ratings), but investors should monitor execution on acquisitions and bioprocessing demand trends for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
